JAC Advance Access originally published online on January 27, 2006
Journal of Antimicrobial Chemotherapy 2006 57(3):511-519; doi:10.1093/jac/dkl006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome
1 Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 2 Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan; 3 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taiwan; 4 Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan; 5 Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taiwan
Received 12 November 2005; returned 20 November 2005; revised 25 December 2005; accepted 27 December 2005
* Correspondence address. Tel: +886-2-2312-3456 ext. 5401; Fax: +886-2-23971412; E-mail: sc4030{at}ha.mc.ntu.edu.tw.
Objectives: To evaluate whether appropriate early empirical glycopeptide therapy improves outcomes of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia.
Methods: We retrospectively collected the data for all adult patients with confirmed MRSA bacteraemia diagnosed and treated at National Taiwan University Hospital during the period 1 April 1997–31 March 2001, and followed their survival up to three years. The main outcome measures were MRSA-related death and all-cause mortality.
Results: There were 77 MRSA-related deaths among 162 patients. There was no statistically significant difference in MRSA-related deaths between patients receiving glycopeptides before or within 48 h after blood culture (n = 43) (55%, 18/33, non-septic shock group; 90%, 9/10, septic shock group) or those whose glycopeptide therapy was begun more than 48 h after blood culture (n = 119) (37%, 40/107, non-septic shock group; 83%, 10/12, septic shock group) (P = 0.11 and 1.00, respectively). The outcome measure of all-cause mortality from 30 days to 3 years yields similar results. Multivariate logistic regression analysis and Cox analysis showed that the length of delay (daily increment) between blood culture sampling and start of glycopeptide therapy did not have a statistically significant impact on MRSA-related death or all-cause 30-day mortality after adjusting for the effect of other variables [adjusted odds ratio 0.99, 95% confidence interval (95% CI) 0.88–1.12; adjusted hazard ratio 0.87, 95% CI 0.74–1.02, respectively).
Conclusions: The hypothesis that earlier empirical use of glycopeptide therapy reduces mortality in patients with hospital-acquired MRSA bacteraemia was not supported.
Keywords: vancomycin , teicoplanin , nosocomial infections , prognosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. P. MacGowan and on behalf of the BSAC Working Parties on Resistanc Clinical implications of antimicrobial resistance for therapy J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii105 - ii114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Leibovici and M. Paul Comment on Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK J. Antimicrob. Chemother., July 1, 2006; 58(1): 220 - 220. [Full Text] [PDF]
|
|